Tan, L., Su, X., Li, X., Li, H., & Hu, B. (2020). Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy. Int J Clin Exp Pathol.
シカゴスタイル引用形Tan, Lun, Xinyu Su, Xun Li, Hai Li, , Bo Hu. "Correlation of HER2 Codon 655 Polymorphism With Cardiotoxicity Risk in Chinese HER2-positive Breast Cancer Patients Undergoing Epirubicin/cyclophosphamide Followed By Docetaxel Plus Trastuzumab Adjuvant Chemotherapy." Int J Clin Exp Pathol 2020.
MLA引用形式Tan, Lun, et al. "Correlation of HER2 Codon 655 Polymorphism With Cardiotoxicity Risk in Chinese HER2-positive Breast Cancer Patients Undergoing Epirubicin/cyclophosphamide Followed By Docetaxel Plus Trastuzumab Adjuvant Chemotherapy." Int J Clin Exp Pathol 2020.